IQVIA Exceeds Q2 Earnings Expectations with Strong Revenue and Booking Growth
IQVIA Holdings Inc. (NYSE:IQV) reported second-quarter results that exceeded expectations, driven by strong revenue growth and increased R&D Solutions bookings. The company recorded $4.368 billion in revenue for the quarter, up 8.7% year over year, with adjusted EBITDA rising to $994 million (+9.2%) and adjusted EPS reaching $3.15 (+12.1%). R&D Solutions saw particularly robust performance, with bookings increasing by 19.3% to $3.15 billion in Q2, contributing to a backlog of $34.2 billion. IQVIA also raised its full-year outlook for revenue ($17.275–$17.475 billion), adjusted EBITDA ($4.0–$4.05 billion) and adjusted EPS ($12.80–$13.00). The company attributed the strong performance to improving market conditions, operational productivity gains, and increased customer demand across its R&D Solutions segment. Management highlighted that emerging biopharma companies are a growing source of innovation in clinical trials and account for 70% of global trial starts today—up from 45% over the past decade. The company is also investing heavily in AI-driven initiatives to further enhance productivity.
Tickers: $IQV
Topics: ebitda eps financial_results outlook_update revenue_growth